Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes.

Maria RyaboshapkinaRegina YeYumei YeYochai Birnbaum

Published in: Cardiovascular drugs and therapy (2023)

SGLT2 had negligible expression in heart tissue. Dapagliflozin improved cardiac metabolism by decreasing glycolysis and pyruvate utilization enzymes, induced antioxidant enzymes, and decreased expression of hypoxia markers. Expression of inflammation, apoptosis, and hypertrophy pathways was decreased. These observations corresponded to the effects of dapagliflozin in the clinical trials.

Keyphrases

poor prognosis
gene expression
oxidative stress
clinical trial
heart failure
dna methylation
randomized controlled trial
cell death
metabolic syndrome
adipose tissue
diabetic rats
high glucose
anti inflammatory
insulin resistance
open label
drug induced
phase iii
wild type